Don't expect a recovery in the Chinese market; it will likely last only 1-2 years at most. The recent increase in revenue reported for the Chinese market is due to very specific reasons—you might want to ask a Chinese friend for more insights.As for FDA approval, it may come around OCT next year. I believe it won't change BUB's fundamentals, but it will likely give a temporary boost to the share price, setting the stage for another CR in 2025.Among the Top 20 shareholders, there are many Chinese names. I can roughly guess their thinking—they're betting on BUB's outcome being SAME to Bellamy's.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.010(6.25%) |
Mkt cap ! $151.8M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 17.0¢ | 15.5¢ | $1.233M | 7.550M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 43000 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 3057777 | 36 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| BUB (ASX) Chart |